Wednesday, July 8, 2026

pharma · Moderately to Severely Active Rheumatologic Disease · Moderately to Severely Active Ulcerative Colitis · SYRE

Spyre Therapeutics

News and analysis for Spyre Therapeutics on NovaPharmaNews — regulatory, clinical, and market coverage.

Waltham, USA HQ
2023 Founded
110 Employees
Public company Type
SYRE · NYSE Ticker
Company details
Status
Public
HQ
Waltham, USA
Founded
2023
Employees
110
Programs
8
Drugs
1
Patents
0
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Spyre Therapeutics — regulatory, clinical, and market coverage.

News and analysis for Spyre Therapeutics on NovaPharmaNews — regulatory, clinical, and market coverage.

No coverage yet

We have not published news or analysis mentioning Spyre Therapeutics yet.

Back to company overview →